PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,696 | -69.5% | 3,828 | -57.9% | 0.00% | – |
| Q2 2023 | $130,083 | +1826.0% | 9,084 | +860.3% | 0.00% | – |
| Q1 2023 | $6,754 | -46.8% | 946 | -16.4% | 0.00% | – |
| Q4 2022 | $12,701 | -9.3% | 1,132 | -9.2% | 0.00% | – |
| Q3 2022 | $14,000 | -33.3% | 1,247 | -50.3% | 0.00% | – |
| Q2 2022 | $21,000 | -27.6% | 2,509 | +19.7% | 0.00% | – |
| Q1 2022 | $29,000 | -80.3% | 2,096 | -71.9% | 0.00% | – |
| Q4 2021 | $147,000 | -16.5% | 7,451 | +36.0% | 0.00% | – |
| Q3 2021 | $176,000 | +83.3% | 5,480 | +93.0% | 0.00% | – |
| Q2 2021 | $96,000 | +39.1% | 2,840 | +53.8% | 0.00% | – |
| Q1 2021 | $69,000 | -37.3% | 1,847 | -43.9% | 0.00% | – |
| Q4 2020 | $110,000 | +168.3% | 3,294 | +194.6% | 0.00% | – |
| Q3 2020 | $41,000 | -61.7% | 1,118 | -65.7% | 0.00% | – |
| Q2 2020 | $107,000 | +28.9% | 3,262 | +0.6% | 0.00% | – |
| Q1 2020 | $83,000 | +23.9% | 3,241 | +50.2% | 0.00% | – |
| Q4 2019 | $67,000 | – | 2,158 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |